secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2023-10-03T23:59:59+00:00
Accession:  0001104659-23-106399
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix initiates first pivotal trial of OTX-TKI for wet AMD
-----------------------------------------------------------------------

- Activated first US clinical trial site; expects to enroll first subject by year-end 2023.
- Superiority trial of ~300 evaluable treatment-naïve wet AMD subjects randomized to aflibercept or OTX-TKI implant.
- Filed Special Protocol Assessment request with FDA for trial design; enrollment will wait for SPA feedback.
- OTX-TKI is an axitinib intravitreal implant, a potential long-acting therapy for wet AMD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923106399/0001104659-23-106399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923106399/tm2327569d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-106399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer